Figure 4From: Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratificationPatient survival stratified for disease stages. Patients with stage IIIb disease showed significant shorter survival (12 ± 5 months; P < 0.001) compared to patients in stage I (117 ± 11 months), IIa (74 ± 9 months), IIb (49 ± 0 months), IIIa (46 ± 0 months) and IV (80 ± 23 months). Between stage I, IIa, IIb, IIIa and IV no statistically significant difference could be found.Back to article page